In today's world, Trepipam is a relevant topic and of great interest to a wide spectrum of people. From its impact on society to its implications on daily life, Trepipam is an issue that deserves attention and in-depth analysis. Whether it is a recent event, a public figure or a global phenomenon, Trepipam continues to generate debate and interest in different areas. In this article, we will explore different aspects and perspectives related to Trepipam, with the aim of expanding understanding and reflection on its importance in our current reality.
| Clinical data | |
|---|---|
| Other names | SCH-12679; SCH12679 |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C19H23NO2 |
| Molar mass | 297.398 g·mol−1 |
| 3D model (JSmol) | |
| Specific rotation | +31.8° |
| Density | 1.072 ± 0.06 g/cm3 (predicted) |
| Melting point | 105–106 °C (221–223 °F) (experimental) |
| Boiling point | 416.8 ± 45.0 °C (782.2 ± 81.0 °F) (predicted) |
| |
| |
Trepipam (INN; developmental code name SCH-12679) is a dopamine receptor agonist of the benzazepine group that was never marketed.[1] It acts specifically as an agonist of the dopamine D1 receptor.[2] It is closed related structurally to fenoldopam, a peripherally acting selective D1 receptor partial agonist which is used as an antihypertensive agent.